Pancreatic cancer has the lowest survival rate of any major cancer, with a five-year survival rate of just 7% across all stages. But it’s not alone at the bottom. Several cancers, including mesothelioma, small cell lung cancer, and glioblastoma, have survival rates so low that they’re collectively known as “less survivable cancers.” What these diseases share is a tendency to hide until they’ve already spread.
Pancreatic Cancer: The Lowest Overall
Pancreatic cancer kills roughly 93 out of every 100 people diagnosed with it within five years. Three in five cases aren’t caught until the cancer has already reached an advanced stage, which is the core reason survival is so poor. Early-stage pancreatic cancer rarely causes obvious symptoms. When it does produce warning signs, they tend to be vague: indigestion, stomach pain, unexplained weight loss. These overlap with dozens of less serious conditions, which means patients and doctors alike can miss the diagnosis for months.
There is no widely available screening test for pancreatic cancer in the general population. By the time imaging confirms a tumor, surgery is often no longer an option because the cancer has spread to surrounding blood vessels, the liver, or other organs. Even among those who do qualify for surgery, recurrence rates are high.
Other Cancers With Very Low Survival
Mesothelioma
Pleural mesothelioma, which forms in the lining of the lungs and is strongly linked to asbestos exposure, has a five-year survival rate of about 15% across all stages. Even when caught at the localized stage, before it has spread, only 23% of patients survive five years. At the distant stage, that number drops to 11%. Mesothelioma is rare but exceptionally aggressive, and symptoms like chest pain and shortness of breath often don’t appear until decades after asbestos exposure.
Small Cell Lung Cancer
Small cell lung cancer is the more aggressive of the two main lung cancer types and carries a five-year survival rate of just 5% to 10% overall. For patients diagnosed with limited-stage disease, where the cancer is confined to one side of the chest, median survival is 16 to 24 months and the five-year rate reaches about 14%. But most patients are diagnosed after the cancer has already spread, which pulls the overall numbers down sharply. Small cell lung cancer grows and metastasizes faster than non-small cell lung cancer, and while it initially responds well to chemotherapy, it almost always returns.
Glioblastoma
Glioblastoma is the most aggressive type of brain cancer. People diagnosed with it live an average of 12 to 18 months even with treatment. About 40% survive one year, and only 17% make it to two years. Five-year survival data is so low it’s rarely even reported as a headline statistic. Glioblastoma tumors are difficult to remove completely because they send microscopic tendrils into surrounding brain tissue, and they are highly resistant to both radiation and chemotherapy.
Gallbladder Cancer
Gallbladder cancer is another cancer that’s far more lethal when caught late. At the localized stage, five-year survival is a reasonable 67%. But once it spreads to distant parts of the body, survival plummets to just 4%. Like pancreatic cancer, gallbladder cancer often produces no symptoms early on, and the gallbladder’s location deep in the abdomen makes tumors easy to miss on routine exams.
Why These Cancers Are So Deadly
The cancers with the worst survival rates share a pattern: they’re diagnosed too late. About one in three patients with a less survivable cancer is only diagnosed after an emergency hospital admission. For more common cancers with better outcomes, late-stage diagnosis happens in roughly 15% of cases. That gap in timing is one of the biggest drivers of the survival difference.
The symptoms of these cancers tend to be nonspecific. Liver cancer, for instance, usually produces no symptoms at an early stage at all. When patients do visit a doctor with vague complaints like fatigue or abdominal discomfort, the overlap with common, benign conditions can delay referral for specialized testing. Each week of delay narrows the treatment window.
Biology plays a role too. Some of these cancers are inherently more resistant to treatment. Glioblastoma, for example, grows in a way that makes complete surgical removal nearly impossible. Small cell lung cancer responds initially to chemotherapy but develops resistance quickly. Pancreatic tumors are surrounded by dense tissue that limits how well drugs can penetrate them.
How Immunotherapy Is Changing the Picture
Immunotherapy has transformed outcomes for several cancers, including melanoma, kidney, and bladder cancers. For melanoma specifically, a treatment that blocks the immune system’s “off switch” can produce 10-year survival in some patients who previously had no long-term options. The number of cancer types successfully treated with immunotherapy has grown to at least 15.
For the lowest-survival cancers, though, progress has been slower. Overall response rates to immunotherapy drugs sit around 15% to 20%, and scientists still don’t fully understand why the majority of patients don’t respond. Pancreatic cancer in particular has proven resistant to most immunotherapy approaches tested so far, largely because its tumors create a microenvironment that suppresses immune activity. Research is ongoing, but for now, these cancers remain the hardest to treat and the most important targets for earlier detection.